Asset profile
ICP-490
Small molecule
Evidence outlook · results not reported
NCT05719701 · Relapsed and/or Refractory Multiple Myeloma
The lead study uses a design that frequently fails to replicate under controlled conditions, and its results have not been reported. This tier describes the design, not an outcome.
NCT05719701: This is an unblinded, non-randomized dose-finding study with no control arm, and no results have been posted yet, so it cannot currently demonstrate a controlled treatment effect.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 61 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| ICP-490: this drug | Phase 1/2 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | ||
| Pomalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Cereblon (CRBN) | ||
| Thalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Iberdomide | Phase 3 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Mezigdomide | Phase 3 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Cemsidomide | Phase 2 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| TQB3820 | Phase 1 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 |
…and 52 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
July 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.